Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
REGN Stock Chart & Stats
$575.69
$9.02(1.24%)
At close: 4:00 PM EST
$575.69
$9.02(1.24%)
Day’s Range― - ―
52-Week Range$476.49 - $952.02
Previous CloseN/A
Volume208.99K
Average Volume (3M)1.08M
Market Cap
$61.40B
Enterprise Value$52.23B
Total Cash (Recent Filing)$7.47B
Total Debt (Recent Filing)$2.71B
Price to Earnings (P/E)14.6
Beta0.81
Next Earnings
Oct 28, 2025EPS Estimate
9.62Last Dividend Ex-Date
Aug 18, 2025Dividend Yield0.46%
Share Statistics
EPS (TTM)12.89
Shares Outstanding104,170,296
10 Day Avg. Volume1,000,807
30 Day Avg. Volume1,078,381
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue3.67
Enterprise Value/Gross Profit4.48
Enterprise Value/Ebitda9.63
Forecast
1Y Price Target
$731.81Price Target Upside27.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
Bulls Say, Bears Say
Bulls Say
Growth DriversDupixent has become the definitive growth driver for Regeneron, maintaining better efficacy and safety compared to competitors.
Pipeline PotentialRegeneron's pipeline, including Factor XI and LAG3, is now critical and could lead to future growth.
Regulatory ApprovalsFDA has granted approval to Libtayo as the first and only immunotherapy for the adjuvant treatment of cutaneous squamous cell carcinoma in patients with a high risk of recurrence following surgery and radiation.
Bears Say
Manufacturing ChallengesIssues at the Catalent manufacturing facility may delay the approval of EYLEA HD prefilled syringe, and Regeneron is seeking an alternative manufacturer.
Market CompetitionEYLEA is expected to face continued pressure from biosimilars and competition, leading to a decrease in demand.
Medicare ExposureREGN’s high Medicare Part B exposure could create an issue under an MFN framework.
Regeneron News
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $476.49 and its highest was $952.02 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is $61.40B.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Oct 28, 2025 which is in 4 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Aug 07, 2025. The company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.431 by $4.459.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron pays a Quarterly dividend of $0.88 which represents an annual dividend yield of 0.46%. See more information on Regeneron dividends here
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 9.62.
How many shares outstanding does Regeneron have?
Regeneron has 104,170,296 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $12.89 in its last earnings report, beating expectations of $8.431. Following the earnings report the stock price went up 0.841%.
Which hedge fund is a major shareholder of Regeneron?
Currently, no hedge funds are holding shares in REGN
Regeneron Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$731.81 (27.12% Upside)
$731.81 (27.12% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 9.1%
Last 30 Days ▲ 9.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.58%
12-Months-Change
Fundamentals
Return on Equity
15.34%
Trailing 12-Months
Asset Growth
5.91%
Trailing 12-Months
Company Description
Regeneron
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for the treatment of serious conditions. Headquartered in Tarrytown, New York, Regeneron operates primarily in the biotechnology sector, developing drugs in therapeutic areas including ophthalmology, immunology, oncology, and cardiovascular diseases. The company is known for its flagship products such as Eylea, a treatment for eye diseases, and Dupixent, used for various allergic and inflammatory conditions.
REGN Company Deck
REGN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Regeneron showed strong performance in key products like Dupixent and Libtayo, successful launches, and robust financial results, offsetting the declines in EYLEA sales and regulatory delays. The company's significant R&D investments indicate a focus on future growth, despite facing competitive pressures and market dynamics.View all REGN earnings summariesREGN Revenue Breakdown
53.72% Net product sales
42.65% Collaboration revenue
3.63% Other
REGN Stock 12 Month Forecast
Average Price Target
$731.81
▲(27.12% Upside)
Technical Analysis
Ownership Overview
0.26% Insiders
27.28% Mutual Funds
0.70% Other Institutional Investors
44.44% Public Companies and Individual Investors
Options Prices
Currently, No data available
---